Not available
Quote | Vaxart Inc. (NASDAQ:VXRT)
Last: | $0.9588 |
---|---|
Change Percent: | -1.96% |
Open: | $1.04 |
Close: | $0.9588 |
High: | $1.04 |
Low: | $0.95 |
Volume: | 1,504,052 |
Last Trade Date Time: | 05/17/2024 03:00:00 am |
News | Vaxart Inc. (NASDAQ:VXRT)
2024-05-13 17:49:08 ET Vaxart, Inc. (VXRT) Q1 2024 Earnings Conference Call May 13, 2024 4:30 p.m. ET Company Participants Ed Berg - Senior Vice President and General Counsel Steven Lo - Chief Executive Officer Sean Tucker - Founder and Chief Scientific Officer ...
2024-05-13 17:01:34 ET More on Vaxart Vaxart, Inc. (VXRT) Q4 2023 Earnings Call Transcript Vaxart GAAP EPS of -$0.14 in-line, revenue of $2.18M beats by $1.38M Vaxart FY 2023 Earnings Preview Seeking Alpha’s Quant Rating on Vaxart Historical ea...
Message Board Posts | Vaxart Inc. (NASDAQ:VXRT)
Subject | By | Source | When |
---|---|---|---|
$VXRT Vaxart Inc | mick | investorshub | 04/30/2023 9:08:27 PM |
disappointing $VXRT | mick | investorshub | 04/15/2023 3:12:46 PM |
$VXRT Vaxart Inc | mick | investorshub | 02/27/2023 12:07:52 AM |
$VXRT Vaxart Inc | mick | investorshub | 02/06/2023 12:26:04 AM |
Too quiet here? The Bill and Melinda | Chuck8032 | investorshub | 01/31/2023 3:50:21 PM |
News, Short Squeeze, Breakout and More Instantly...
Vaxart, Inc. (NASDAQ:VXRT) reported its first-quarter financial results after the bell Monday. Here's a look at the details. The Details...
Positive results from Phase 1 norovirus study in lactating mothers indicate the potential of Vaxart’s oral pill vaccine candidate to protect or reduce the effect of the disease in infants Expects to initiate Phase 2b study evaluating Vaxart’s oral pill XBB COVID-19 vaccine a...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...